R
Riboway Therapeutics develops AI-powered technology to precisely control protein expression by targeting RNA. This platform enables the upregulation, downregulation, activation, or inhibition of target proteins based on therapeutic requirements. The company focuses on assets for neurodegenerative and metabolic diseases, including novel antisense oligonucleotide (ASO) programs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Riboway Therapeutics develops therapeutics by precisely controlling protein expression and function through RNA targeting. Their AI-based platform decodes RNA regulation to identify druggable angles for modulating target proteins. This technology enables the precise upregulation, downregulation, activation, or inhibition of proteins for treating neurodegenerative and metabolic diseases.